Breaking News Instant updates and real-time market news.

MASI

Masimo

$155.76 /

+8.1 (+5.49%)

08:21
03/25/20
03/25
08:21
03/25/20
08:21

Masimo says results of 10-year Masimo SET, Patient SafetyNet study published

Masimo announced the results of a recently published ten-year retrospective study in which researchers at Dartmouth-Hitchcock Medical Center investigated the impact of an integrated clinical surveillance monitoring system, using Masimo SET and Patient SafetyNet technologies, on mortality related to use of prescribed opioids in the general ward. Over the ten years studied, of 111,488 patients in units with surveillance available, there were zero patient deaths and no patients were harmed by opioid-induced respiratory depression while continuous monitoring was in use. In contrast, among patients in units without surveillance available, there were three deaths.The surveillance monitoring system provided continuous monitoring using Masimo SET measure-through motion and low perfusion pulse oximetry, and was comprised of Masimo Radical-7 and Rad-87 Pulse CO-Oximeters, Root patient monitoring and connectivity hubs, and Masimo Patient SafetyNet, which provided supplemental remote monitoring at central view stations and alarm and alarm escalation notifications to clinicians' pagers. Monitored parameters included oxygen saturation, or SpO2, and pulse rate, or PR. The researchers reviewed ten years of data collected from 2007 to 2017, over which time there were 126,697 general care unit discharges. Sue McGrath and colleagues at Dartmouth-Hitchcock Medical Center found that, over the 10 years, of the 111,488 patients in units with surveillance monitoring available, "none died or were harmed by opioid-induced respiratory depression when surveillance monitoring was in use." Of the 15,209 patients in unmonitored units, three patients died from opioid overdose. The reduced death rate when surveillance was available, compared to when it was not available, was statistically "significant". A fourth patient died in a unit where surveillance monitoring was available but Masimo technology was not being used at the time of the adverse event.

MASI Masimo
$155.76 /

+8.1 (+5.49%)

03/02/20 Raymond James
Masimo 'well positioned' should COVID-19 expand, says Raymond James
03/02/20 Raymond James
Masimo upgraded to Outperform from Market Perform at Raymond James
02/20/20 Piper Sandler
Masimo price target raised to $201 from $175 at Piper Sandler
01/15/20 Piper Sandler
Masimo should continue 'beat and raise' approach in 2020, says Piper Sandler

TODAY'S FREE FLY STORIES

Options
AT&T put buyer realizes 13% same-day gains » 08:00
03/30/20
03/30
08:00
03/30/20
08:00
T

AT&T

$29.86 /

-0.68 (-2.23%)

Notable profits for the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Orgenesis CEO says "well-positioned" to drive long-term shareholder value » 08:00
03/30/20
03/30
08:00
03/30/20
08:00
ORGS

Orgenesis

$3.23 /

-0.095 (-2.86%)

Orgenesis provides the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Cerner upgraded to Outperform from Market Perform at Cowen » 08:00
03/30/20
03/30
08:00
03/30/20
08:00
CERN

Cerner

$59.93 /

-1.09 (-1.79%)

As reported previously,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Morgan Stanley ups Cognizant to Equal Weight as slower transformation priced in » 07:59
03/30/20
03/30
07:59
03/30/20
07:59
CTSH

Cognizant

$46.59 /

-3.23 (-6.48%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Wendy's price target lowered to $15 from $24 at Piper Sandler » 07:59
03/30/20
03/30
07:59
03/30/20
07:59
WEN

Wendy's

/

+

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Masonite price target lowered to $82 from $95 at Wedbush » 07:59
03/30/20
03/30
07:59
03/30/20
07:59
DOOR

Masonite

$45.06 /

-8.03 (-15.13%)

Wedbush analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Rhythm Pharmaceuticals completes rolling submission of NDA for setmelanotide » 07:58
03/30/20
03/30
07:58
03/30/20
07:58
RYTM

Rhythm Pharmaceuticals

$14.06 /

-0.58 (-3.96%)

Rhythm Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Darden price target raised to $63 from $50 at Piper Sandler » 07:58
03/30/20
03/30
07:58
03/30/20
07:58
DRI

Darden

$54.67 /

-5.94 (-9.80%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Oyster Point Pharma experiences impact to trial sites amid COVID-19 » 07:57
03/30/20
03/30
07:57
03/30/20
07:57
OYST

Oyster Point Pharma

$35.14 /

-0.21 (-0.59%)

Due to the COVID-19…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Carvana price target lowered to $67 from $100 at Baird » 07:57
03/30/20
03/30
07:57
03/30/20
07:57
CVNA

Carvana

/

+

Baird analyst Colin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Masonite removed from Best Ideas List at Wedbush » 07:57
03/30/20
03/30
07:57
03/30/20
07:57
DOOR

Masonite

$45.06 /

-8.03 (-15.13%)

Wedbusha removed Masonite…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Tempur Sealy a favored 'bounce-back' idea for 2021 at Piper Sandler » 07:57
03/30/20
03/30
07:57
03/30/20
07:57
TPX

Tempur Sealy

$45.92 /

-2.09 (-4.35%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Oyster Point Pharma completes enrollment in ONSET-2 Phase 3 trial of OC-01 » 07:57
03/30/20
03/30
07:57
03/30/20
07:57
OYST

Oyster Point Pharma

$35.14 /

-0.21 (-0.59%)

Oyster Point Pharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Pluristem treats first three COVID-19 patients in Israel under compassionate use » 07:56
03/30/20
03/30
07:56
03/30/20
07:56
PSTI

Pluristem

$3.06 /

-0.175 (-5.42%)

Pluristem Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Immunovant announces clinical results from ongoing Phase 2a study of IMVT-1401 » 07:55
03/30/20
03/30
07:55
03/30/20
07:55
IMVT

Immunovant

$13.54 /

+0.92 (+7.29%)

Immunovant announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Moderna to host conference call » 07:55
03/30/20
03/30
07:55
03/30/20
07:55
MRNA

Moderna

$30.01 /

+2.1 (+7.52%)

Management holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Bruker price target lowered to $46 from $58 at SVB Leerink » 07:54
03/30/20
03/30
07:54
03/30/20
07:54
BRKR

Bruker

$36.72 /

-3.52 (-8.75%)

SVB Leerink analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cytokinetics announces baseline characteristics from GALACTIC-HF » 07:54
03/30/20
03/30
07:54
03/30/20
07:54
CYTK

Cytokinetics

$11.73 /

+0.29 (+2.53%)

Cytokinetics,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Global Blood selloff prices in Oxbryta delay, says Piper Sandler » 07:53
03/30/20
03/30
07:53
03/30/20
07:53
GBT

Global Blood Therapeutics

$51.16 /

-0.83 (-1.60%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
HSBC downgraded to Neutral from Buy at BofA » 07:53
03/30/20
03/30
07:53
03/30/20
07:53
HSBC

HSBC

$28.85 /

-1.3 (-4.31%)

BofA analyst Alastair…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
MediWound temporarily suspends enrollment in EscharEx phase 2 study » 07:52
03/30/20
03/30
07:52
03/30/20
07:52
MDWD

MediWound

$1.70 /

+0.01 (+0.59%)

MediWound provided an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Stericycle upgraded to Outperform from Neutral at Baird » 07:51
03/30/20
03/30
07:51
03/30/20
07:51
SRCL

Stericycle

$42.05 /

-0.98 (-2.28%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Hostess Brands upgraded to Buy from Hold at Berenberg » 07:51
03/30/20
03/30
07:51
03/30/20
07:51
TWNK

Hostess Brands

$10.15 /

-0.055 (-0.54%)

Berenberg analyst Donald…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Kiniksa highlights analysis from Phase 2 trial of rilonacept » 07:50
03/30/20
03/30
07:50
03/30/20
07:50
KNSA

Kiniksa

$12.57 /

-0.74 (-5.56%)

Kiniksa Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Axsome Therapeutics to host conference call » 07:49
03/30/20
03/30
07:49
03/30/20
07:49
AXSM

Axsome Therapeutics

$63.27 /

-0.17 (-0.27%)

Management holds a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.